Literature DB >> 19635045

Good and poor adherence: optimal cut-point for adherence measures using administrative claims data.

Sudeep Karve1, Mario A Cleves, Mark Helm, Teresa J Hudson, Donna S West, Bradley C Martin.   

Abstract

OBJECTIVE: To identify the adherence value cut-off point that optimally stratifies good versus poor compliers using administratively derived adherence measures, the medication possession ratio (MPR) and the proportion of days covered (PDC) using hospitalization episode as the primary outcome among Medicaid eligible persons diagnosed with schizophrenia, diabetes, hypertension, congestive heart failure (CHF), or hyperlipidemia. RESEARCH DESIGN AND METHODS: This was a retrospective analysis of Arkansas Medicaid administrative claims data. Patients > or =18 years old had to have at least one ICD-9-CM code for the study diseases during the recruitment period July 2000 through April 2004 and be continuously eligible for 6 months prior and 24 months after their first prescription for the target condition. Adherence rates to disease-specific drug therapy were assessed during 1 year using MPR and PDC. MAIN OUTCOME MEASURE AND ANALYSIS SCHEME: The primary outcome measure was any-cause and disease-related hospitalization. Univariate logistic regression models were used to predict hospitalizations. The optimum adherence value was based on the adherence value that corresponded to the upper most left point of the ROC curve corresponding to the maximum specificity and sensitivity.
RESULTS: The optimal cut-off adherence value for the MPR and PDC in predicting any-cause hospitalization varied between 0.63 and 0.89 across the five cohorts. In predicting disease-specific hospitalization across the five cohorts, the optimal cut-off adherence values ranged from 0.58 to 0.85.
CONCLUSIONS: This study provided an initial empirical basis for selecting 0.80 as a reasonable cut-off point that stratifies adherent and non-adherent patients based on predicting subsequent hospitalization across several highly prevalent chronic diseases. This cut-off point has been widely used in previous research and our findings suggest that it may be valid in these conditions; it is based on a single outcome measure, and additional research using these methods to identify adherence thresholds using other outcome metrics such as laboratory or physiologic measures, which may be more strongly related to adherence, is warranted.

Entities:  

Mesh:

Year:  2009        PMID: 19635045     DOI: 10.1185/03007990903126833

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  151 in total

1.  Association between sitagliptin adherence and self-monitoring of blood glucose.

Authors:  Somesh Nigam; Naunihal S Virdi; Mehmet Daskiran; Chris M Kozma; Andrew Paris; William M Dickson
Journal:  J Diabetes Sci Technol       Date:  2012-05-01

2.  Assessment of adherence to disease-modifying anti-rheumatic drugs in rheumatoid arthritis.

Authors:  Clélia Monchablon; Henri Gondé; Sophie Pouplin; Rémi Varin; Olivier Vittecoq; Thierry Lequerré
Journal:  Clin Rheumatol       Date:  2019-11-26       Impact factor: 2.980

Review 3.  The effectiveness of interventions using electronic reminders to improve adherence to chronic medication: a systematic review of the literature.

Authors:  Marcia Vervloet; Annemiek J Linn; Julia C M van Weert; Dinny H de Bakker; Marcel L Bouvy; Liset van Dijk
Journal:  J Am Med Inform Assoc       Date:  2012-04-25       Impact factor: 4.497

4.  Predictors of first-year nonadherence and discontinuation of statins among older adults: a retrospective cohort study.

Authors:  Richard Ofori-Asenso; Jenni Ilomäki; Mark Tacey; Si Si; Andrea J Curtis; Ella Zomer; J Simon Bell; Sophia Zoungas; Danny Liew
Journal:  Br J Clin Pharmacol       Date:  2018-11-08       Impact factor: 4.335

5.  Impact of cancer on adherence to glucose-lowering drug treatment in individuals with diabetes.

Authors:  Marjolein M J Zanders; Harm R Haak; Myrthe P P van Herk-Sukel; Lonneke V van de Poll-Franse; Jeffrey A Johnson
Journal:  Diabetologia       Date:  2015-02-01       Impact factor: 10.122

6.  Statistical considerations for medication adherence research.

Authors:  Josh DeClercq; Leena Choi
Journal:  Curr Med Res Opin       Date:  2020-07-22       Impact factor: 2.580

7.  The Association Between Changes in Alcohol Use and Changes in Antiretroviral Therapy Adherence and Viral Suppression Among Women Living with HIV.

Authors:  Nikita Barai; Anne Monroe; Catherine Lesko; Bryan Lau; Heidi Hutton; Cui Yang; Anika Alvanzo; Mary Elizabeth McCaul; Geetanjali Chander
Journal:  AIDS Behav       Date:  2017-07

8.  Beliefs about GI medications and adherence to pharmacotherapy in functional GI disorder outpatients.

Authors:  Benjamin Cassell; C Prakash Gyawali; Vladimir M Kushnir; Britt M Gott; Billy D Nix; Gregory S Sayuk
Journal:  Am J Gastroenterol       Date:  2015-04-28       Impact factor: 10.864

9.  The effects of antitussive treatment of ACE inhibitor-induced cough on therapy compliance: a prescription sequence symmetry analysis.

Authors:  Stefan Vegter; Pieter de Boer; Klaas Willem van Dijk; Sipke Visser; Lolkje T W de Jong-van den Berg
Journal:  Drug Saf       Date:  2013-06       Impact factor: 5.606

10.  Oral therapy adherence and satisfaction in patients with multiple myeloma.

Authors:  Marine Solano; Etienne Daguindau; Cyril Faure; Pierre Loriod; Coline Pain; Anne-Cécile Maes; Pauline Marguet; Marie Kroemer; Anne Rumpler; Jean Fontan; Eric Deconinck; Samuel Limat; Anne-Laure Clairet
Journal:  Ann Hematol       Date:  2021-05-03       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.